What you’re about to view is Part 1 of 2 of a portfolio protection bull versus bear themed series on Retractable Technologies, Inc. (NYSE:RVP), a company that makes retractable syringes and is addressing a global billion-dollar needlestick problem. The company received a COVID-19 contract in 2020 to help with the administration of the vaccines. On this news, the stock climbed from a $1.50 to over $21 and ended up being one of our best performing stocks last year.
But recently, with COVID-19 nearly in the rearview mirror, and a short seller report by Bleecker Street Research, the stock has come down sharply, now trading in the $9 range. So, we address some of the concerns in the short report, and some other concerns investors might have regarding the growth challenges that RVP faces outside of that.
I discussed the above with Jan Svenda, one of my research analysts who helps me with research from time to time at GeoInvesting. Please enjoy the video and if you have any questions, feel free to comment below and we’ll address them as best as we can.
Log in below with your Premium Account to view the video or check us out with a free trial.